Regeneron and Sanofi announce positive results from phase 2b study of dupilumab in patients with moderate-to-severe atopic dermatitis

Wednesday, 9 Jul 2014 05:00pm EDT 

Regeneron Pharmaceuticals Inc:Says that the company and Sanofi announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared to placebo.Dupilumab is an investigational monoclonal antibody that blocks signaling of IL-4 and IL-13, two cytokines that play a key role in the pathogenesis of moderate-to-severe atopic dermatitis. 

Company Quote

-0.65 -0.86%
24 Dec 2014